Currently out of the existing stock ratings of Christopher Marai, 138 are a BUY (86.25%), 7 are a HOLD (4.38%), 15 are a SELL (9.38%).

Christopher Marai

Work Performance Price Targets & Ratings Chart

Analyst Christopher Marai, carries an average stock price target met ratio of 56.75% that have a potential upside of 62.8% achieved within 400 days. Previously, Christopher Marai worked at NOMURA, OPPENHEIMER.

Christopher Marai’s has documented 317 price targets and ratings displayed on 28 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on CRBP, Corbus Pharmaceuticals at 04-Jun-2020.

Wall Street Analyst Christopher Marai

Analyst best performing recommendations are on DCPH (DECIPHERA PHARMACEUTICALS LLC).
The best stock recommendation documented was for DCPH (DECIPHERA PHARMACEUTICALS LLC) at 10/23/2017. The price target of $57 was fulfilled within 31 days with a profit of $36.21 (174.17%) receiving and performance score of 56.18.

Average potential price target upside

of $86.94 (89.3%) on ARGX (ARGENX NV ADR).
of $51.99 (17.34%) on BIIB (BIOGEN).
of $34.87 (31.12%) on ALXN (ALEXION PHARMACEUTICALS).

ALNY Alnylam Pharmaceuticals ALXN Alexion Pharmaceuticals BIIB Biogen BMRN Biomarin Pharmaceutical INCY yte PTCT PTC Therapeutics SRPT Sarepta Therapeutics XNCR Xencor FPRX Five Prime Therapeutics QURE Uniqure NV CLLS Cellectis SA GBT Global Blood Therapeutics GLPG Galapagos NV ADR PRTA Prothena plc PTGX Protagonist Therapeutics SLDB Solid Biosciences LLC SNDX Syndax Pharmaceuticals ARGX argenx NV ADR CRBP Corbus Pharmaceuticals DCPH Deciphera Pharmaceuticals LLC IMGN ImmunoGen MGNX MacroGenics MITO Stealth BioTherapeutics Corp VYGR Voyager Therapeutics CTMX CytomX Therapeutics IMVT Immunovant KDMN Kadmon Holdings RTRX Travere Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Paul Matteis (STIFEL)